Literature DB >> 25249013

Ruxolitinib and survival improvement in patients with myelofibrosis.

F Passamonti1, A M Vannucchi2, F Cervantes3, C Harrison4, E Morra5, H Kantarjian6, S Verstovsek6.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25249013     DOI： 10.1038/leu.2014.282

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  8 in total

1.  Unique features of primary myelofibrosis in Chinese.

Authors:  Zefeng Xu; Robert Peter Gale; Yue Zhang; Tiejun Qin; Huishu Chen; Peihong Zhang; Tianjiao Zhang; Liu Liu; Shiqiang Qu; Zhijian Xiao
Journal:  Blood       Date:  2012-01-18       Impact factor: 22.113

2.  Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I.

Authors:  Srdan Verstovsek; Ruben A Mesa; Jason Gotlib; Richard S Levy; Vikas Gupta; John F DiPersio; John V Catalano; Michael W N Deininger; Carole B Miller; Richard T Silver; Moshe Talpaz; Elliott F Winton; Jimmie H Harvey; Murat O Arcasoy; Elizabeth O Hexner; Roger M Lyons; Ronald Paquette; Azra Raza; Kris Vaddi; Susan Erickson-Viitanen; William Sun; Victor Sandor; Hagop M Kantarjian
Journal:  Haematologica       Date:  2013-09-13       Impact factor: 9.941

3.  Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis.

Authors:  Francisco Cervantes; Alessandro M Vannucchi; Jean-Jacques Kiladjian; Haifa Kathrin Al-Ali; Andres Sirulnik; Viktoriya Stalbovskaya; Mari McQuitty; Deborah S Hunter; Richard S Levy; Francesco Passamonti; Tiziano Barbui; Giovanni Barosi; Claire N Harrison; Laurent Knoops; Heinz Gisslinger
Journal:  Blood       Date:  2013-10-30       Impact factor: 22.113

4.  JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis.

Authors:  Claire Harrison; Jean-Jacques Kiladjian; Haifa Kathrin Al-Ali; Heinz Gisslinger; Roger Waltzman; Viktoriya Stalbovskaya; Mari McQuitty; Deborah S Hunter; Richard Levy; Laurent Knoops; Francisco Cervantes; Alessandro M Vannucchi; Tiziano Barbui; Giovanni Barosi
Journal:  N Engl J Med       Date:  2012-03-01       Impact factor: 91.245

5.  Does ruxolitinib improve survival of persons with MPN-associated myelofibrosis? Should it?

Authors:  G Barosi; M-J Zhang; R Peter Gale
Journal:  Leukemia       Date:  2014-07-16       Impact factor: 11.528

6.  Impact of ruxolitinib on the natural history of primary myelofibrosis: a comparison of the DIPSS and the COMFORT-2 cohorts.

Authors:  Francesco Passamonti; Margherita Maffioli; Francisco Cervantes; Alessandro Maria Vannucchi; Enrica Morra; Tiziano Barbui; Domenica Caramazza; Lisa Pieri; Elisa Rumi; Heinz Gisslinger; Laurent Knoops; Jean Jaques Kiladjian; Barbara Mora; Norbert Hollaender; Cristiana Pascutto; Claire Harrison; Mario Cazzola
Journal:  Blood       Date:  2014-01-17       Impact factor: 22.113

7.  A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment).

Authors:  Francesco Passamonti; Francisco Cervantes; Alessandro Maria Vannucchi; Enrica Morra; Elisa Rumi; Arturo Pereira; Paola Guglielmelli; Ester Pungolino; Marianna Caramella; Margherita Maffioli; Cristiana Pascutto; Mario Lazzarino; Mario Cazzola; Ayalew Tefferi
Journal:  Blood       Date:  2009-12-14       Impact factor: 22.113

8.  Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia.

Authors:  A Hochhaus; S G O'Brien; F Guilhot; B J Druker; S Branford; L Foroni; J M Goldman; M C Müller; J P Radich; M Rudoltz; M Mone; I Gathmann; T P Hughes; R A Larson
Journal:  Leukemia       Date:  2009-03-12       Impact factor: 11.528
  8 in total
  5 in total

1.  The impact of ruxolitinib treatment on inflammation-mediated comorbidities in myelofibrosis and related neoplasms.

Authors:  Mads Emil Bjørn; Hans Carl Hasselbalch
Journal:  Clin Case Rep       Date:  2015-05-04

Review 2.  Aberrant Signaling Pathways in T-Cell Acute Lymphoblastic Leukemia.

Authors:  Deborah Bongiovanni; Valentina Saccomani; Erich Piovan
Journal:  Int J Mol Sci       Date:  2017-09-05       Impact factor: 5.923

Review 3.  JAK2 Alterations in Acute Lymphoblastic Leukemia: Molecular Insights for Superior Precision Medicine Strategies.

Authors:  Charlotte Ej Downes; Barbara J McClure; Daniel P McDougal; Susan L Heatley; John B Bruning; Daniel Thomas; David T Yeung; Deborah L White
Journal:  Front Cell Dev Biol       Date:  2022-07-12

Review 4.  The Role of Reactive Oxygen Species in Myelofibrosis and Related Neoplasms.

Authors:  Mads Emil Bjørn; Hans Carl Hasselbalch
Journal:  Mediators Inflamm       Date:  2015-10-11       Impact factor: 4.711

5.  Benefits and pitfalls of pegylated interferon-α2a therapy in patients with myeloproliferative neoplasm-associated myelofibrosis: a French Intergroup of Myeloproliferative neoplasms (FIM) study.

Authors:  Jean-Christophe Ianotto; Aurélie Chauveau; Françoise Boyer-Perrard; Emmanuel Gyan; Kamel Laribi; Pascale Cony-Makhoul; Jean-Loup Demory; Benoit de Renzis; Christine Dosquet; Jerome Rey; Lydia Roy; Brigitte Dupriez; Laurent Knoops; Laurence Legros; Mohamed Malou; Pascal Hutin; Dana Ranta; Omar Benbrahim; Valérie Ugo; Eric Lippert; Jean-Jacques Kiladjian
Journal:  Haematologica       Date:  2017-12-07       Impact factor: 9.941
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.